Efficacy and safety of palbociclib in patients with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer with preexisting conditions:...

por Gelmon, Karen, Walshe, Janice M., Mahtani, Reshma, Joy, Anil A., Karuturi, Meghan, Neven, Patrick, Lu, Dongrui Ray, Kim, Sindy, Schnell, Patrick, Bananis, Eustratios, Schwartzberg, Lee
Publicado 2021

Real-World Tumor Response of Palbociclib in Combination With an Aromatase Inhibitor as First-Line Therapy in Pre/Perimenopausal Women With Metastatic Breast Cancer

por DeMichele, Angela, Robert, Nicholas, Chen, Connie, Kim, Sindy, Zhang, Zhe, Lu, Dongrui Ray, Aguilar, Kathleen M., Wang, Yunfei, Li, Benjamin, Schneeweiss, Sebastian, Rassen, Jeremy A., Gaffney, Michael, McRoy, Lynn
Publicado 2023

Palbociclib plus letrozole as treatment for postmenopausal women with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer for whom le...

por Loi, Sherene, Karapetis, Christos S., McCarthy, Nicole, Oakman, Catherine, Redfern, Andrew, White, Michelle, Khasraw, Mustafa, Doval, Dinesh Chandra, Gore, Vinod, Alam, Mahmood, Binko, Justin, Lu, Dongrui Ray, Kim, Sindy, Boyle, Frances
Publicado 2021

Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma

por Harmon, Charles S., DePrimo, Samuel E., Figlin, Robert A., Hudes, Gary R., Hutson, Thomas E., Michaelson, M. Dror, Négrier, Sylvie, Kim, Sindy T., Huang, Xin, Williams, J. Andrew, Eisen, Tim, Motzer, Robert J.
Publicado 2013

Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative a...

por Rugo, Hope S., Im, Seock-Ah, Joy, Anil A., Shparyk, Yaroslav, Walshe, Janice M., Sleckman, Bethany, Loi, Sherene, Theall, Kathy Puyana, Kim, Sindy, Huang, Xin, Bananis, Eustratios, Mahtani, Reshma, Finn, Richard S., Diéras, Véronique
Publicado 2022

Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast...

por Finn, Richard S., Boer, Katalin, Bondarenko, Igor, Patel, Ravindranath, Pinter, Tamas, Schmidt, Marcus, Shparyk, Yaroslav V., Thummala, Anu, Voitko, Nataliia, Bananis, Eustratios, McRoy, Lynn, Wilner, Keith, Huang, Xin, Kim, Sindy, Slamon, Dennis J., Ettl, Johannes
Publicado 2020

Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from...

por Finn, Richard S., Crown, John P., Ettl, Johannes, Schmidt, Marcus, Bondarenko, Igor M., Lang, Istvan, Pinter, Tamas, Boer, Katalin, Patel, Ravindranath, Randolph, Sophia, Kim, Sindy T., Huang, Xin, Schnell, Patrick, Nadanaciva, Sashi, Bartlett, Cynthia Huang, Slamon, Dennis J.
Publicado 2016

Overall Survival with Palbociclib and Fulvestrant in Women with HR(+)/HER2(−) ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study

por Cristofanilli, Massimo, Rugo, Hope S., Im, Seock-Ah, Slamon, Dennis J., Harbeck, Nadia, Bondarenko, Igor, Masuda, Norikazu, Colleoni, Marco, DeMichele, Angela, Loi, Sherene, Iwata, Hiroji, O'Leary, Ben, André, Fabrice, Loibl, Sibylle, Bananis, Eustratios, Liu, Yuan, Huang, Xin, Kim, Sindy, Lechuga Frean, Maria Jose, Turner, Nicholas C.
Publicado 2022